iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, today announced the appointment of Frances Balkwill, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, to its Scientific Advisory Board (SAB).
September 8, 2022
· 3 min read